Natera, Inc. (NASDAQ:NTRA) Director Sells $590,760.00 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the transaction, the director now owns 9,704 shares of the company's stock, valued at approximately $1,433,183.76. This trade represents a 29.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Natera Price Performance

Shares of NTRA stock traded down $2.97 during trading hours on Tuesday, hitting $146.28. The company's stock had a trading volume of 1,082,800 shares, compared to its average volume of 1,341,487. The business has a fifty day moving average of $163.24 and a 200-day moving average of $149.06. The stock has a market cap of $19.78 billion, a price-to-earnings ratio of -83.11 and a beta of 1.80. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Barclays assumed coverage on shares of Natera in a research note on Thursday, January 23rd. They set an "overweight" rating and a $200.00 target price for the company. Robert W. Baird boosted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Finally, StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $178.12.

Institutional Trading of Natera

A number of hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its stake in Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares during the period. JPMorgan Chase & Co. grew its stake in Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after acquiring an additional 2,036,396 shares during the period. Wellington Management Group LLP grew its stake in Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the period. Norges Bank purchased a new stake in Natera in the 4th quarter worth approximately $224,040,000. Finally, Raymond James Financial Inc. purchased a new stake in Natera in the 4th quarter worth approximately $146,419,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.